Viridian Therapeutics Inc Ordinary Shares VRDN 深 沪
等待开盘 12-20 09:30:00 美东时间
31.94
+0.340
+1.08%
华盛通- 最 高34.04
- 今 开31.66
- 成交量 152.94万股
- 最 低 30.22
- 昨 收 31.60
- 总市值 8.92亿
- 52周最高 34.04
- 市盈率 静 --
- 换手率 5.48%
- 52周最低 9.90
- 委 比 -35.17%
- 总股本 2792.74万
- 历史最高 270.00
- 量 比 1.45
- 振 幅 12.09%
- 历史最低 1.10
- 每 手 1
- 风险率 5.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza
William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA review and VRDN-003 Phase 3 data.
12-04 04:25
百济盈利，再鼎环比翻倍，信达收入52亿，股价却齐跌？创新七君进入重估时刻
对于以“创新七君”为代表的中国头部Biotech来说，已在2024年年报披露时普遍站上盈亏平衡线，2025年则不再是验证能否盈利的一年，而是走进拐点的新周期...
08-13 21:59
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
Analysts' ratings for Viridian Therapeutics (NASDAQ:VRDN) over the last quarter...
2024-09-27 02:00
Viridian Therapeutics To Host Webcast VRDN-001 Phase 3 THRIVE Topline Results On Sept. 10, 2024
- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) -- Conference call and webcast to be held Tuesday, September 10, at 8:00 a.m. ET -
2024-09-10 04:03
RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $35 Price Target
RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $35 price target.
2024-08-28 20:53
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $27 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 price target.
2024-08-15 18:23
